Mark Gelder

Mark Gelder has extensive experience in the pharmaceutical and biotech industry. Mark is currently the Chief Medical Officer at Onconova Therapeutics since June 2021. Before that, they held the same role at Elevar Therapeutics from December 2020 to June 2021, and was also the VP, Head of Medical Affairs there from May 2020 to December 2020. Prior to that, they served as the Head, Americas and Asia Pacific Oncology Medical Directors' Team at Covance from 2018 to May 2020.

From 2016 to 2017, Mark Gelder was the Chief Medical Officer at Pierian Biosciences. Mark also held the positions of EVP, Head of Research and Development from April 2016 to September 2016, and SVP, Head of Clinical Development from January 2016 to April 2016 at the same company. Before that, they served as the Chief Medical Officer at Accelovance, Inc. from September 2015 to January 2016, and was the VP Clinical Development at Inovio Pharmaceuticals Inc. from January 2015 to September 2015.

Prior to these roles, Mark Gelder was the SVP and Chief Medical Officer at Heron Therapeutics, Inc. from December 2012 to January 2015. Mark also worked at GE Healthcare as the VP, Global Head Medical Affairs & PV, Medical Diagnostics/NPD from December 2011 to December 2012, and at Bayer HealthCare as the VP, Global Medical Affairs, Oncology from October 2007 to December 2011. Mark started their career at Wyeth as the Global Therapeutic Area Director, Oncology from 2005 to 2007.

Mark Gelder received their Bachelor of Science degree in Biochemistry and Molecular Biology from Colgate University from 1974 to 1978. Mark then pursued their medical education at the University of Virginia School of Medicine from 1978 to 1982, obtaining their MD degree.